Citius Oncology, Inc. (NASDAQ:CTOR – Get Free Report) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 289,717 shares, a decrease of 43.1% from the September 15th total of 509,543 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 129,388 shares, the short-interest ratio is currently 2.2 days.
Analysts Set New Price Targets
Separately, Weiss Ratings raised Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 16th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company presently has an average rating of “Sell”.
Check Out Our Latest Research Report on CTOR
Citius Oncology Trading Up 0.5%
Shares of NASDAQ CTOR traded up $0.00 during midday trading on Friday, hitting $0.75. The stock had a trading volume of 2,406 shares, compared to its average volume of 153,010. The company has a market capitalization of $69.73 million, a price-to-earnings ratio of -1.60 and a beta of 3.39. Citius Oncology has a 1-year low of $0.49 and a 1-year high of $1.95. The company has a quick ratio of 0.34, a current ratio of 0.73 and a debt-to-equity ratio of 0.25. The company has a fifty day moving average price of $0.87 and a 200 day moving average price of $0.79.
Citius Oncology (NASDAQ:CTOR – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $2.50 million.
Institutional Investors Weigh In On Citius Oncology
An institutional investor recently bought a new stake in Citius Oncology stock. Bank of America Corp DE acquired a new position in Citius Oncology, Inc. (NASDAQ:CTOR – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,835,160 shares of the company’s stock, valued at approximately $2,493,000. Bank of America Corp DE owned approximately 4.12% of Citius Oncology as of its most recent SEC filing. Institutional investors own 70.52% of the company’s stock.
About Citius Oncology
Citius Oncology, Inc (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and related serious diseases. The company was established as an oncology-focused subsidiary of Citius Pharmaceuticals and became a separately traded public company following a business combination.
Citius Oncology’s lead product is LYMPHIR (denileukin diftitox-cxdl), a targeted immunotherapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.
Featured Articles
- Five stocks we like better than Citius Oncology
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
- Palantir’s Potential Next Catalyst After Retail Profit-Taking
- Morgan Stanley Beats on Earnings, But Shares Fall on Trading Mix
- RTX Locks In a Decade of Defense Dominance
Receive News & Ratings for Citius Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
